BIOHAVEN LTD (BHVN)
Health Care · Biotechnology · NYSE
Biohaven is a biopharmaceutical firm developing a diverse pipeline of innovative therapies for complex diseases in neuroscience, immunology, obesity, and oncology.
What BIOHAVEN LTD does
Biohaven is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics across immunology, obesity, neuroscience, and oncology. The company utilizes proprietary drug development platforms, including MoDE and TRAP technologies for extracellular protein degradation and Kv7 ion channel modulation.
Themes: neuroscience, immunology, obesity, oncology, protein degradation
Fundamentals
- Price$13.85 as of 2026-08-21 close
- Market cap$2.1B as of 2026-08-21
- 1-year return-5.7% 2025-08-21 close $14.68 → 2026-08-21 close $13.85
- P/En/a earnings data not available
- ROE-450.0% as of 2026-08-24
- Debt / equity1.87 as of 2026-08-24
- Beta3.09 as of 2026-08-24
- Last reported earnings2026-08-10 SEC EDGAR Form 8-K (Item 2.02)
How BHVN compares in its sector
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
BHVN is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no growth data.
Short-term score
49.7 #812 of 1,704 scored · #141 of 240 in Health Care
Setup 62nd: day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 2% of the past ~6 months), which often precedes a bigger move; momentum 57th: over the past 3 months this stock beat the market by 43.0 percentage points; weakest is trend 35th: it is trading 4.2% below its 50-day average, the short-term trend line.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How BIOHAVEN LTD looks technically
BIOHAVEN LTD (BHVN) is trading 21.7% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 32 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 47, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 4 trading days ago (its momentum flipped negative). It made a new 20-day low about 15 trading days ago. It is 25.4% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 2% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 21.7% above its 200-day average, the long-term trend line — a longer-term uptrend | +21.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $14.45 | $14.45 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $11.38 | $11.38 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 32 calendar days ago — the swings before that are what the structure reading is measured on | 32 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 15.79. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 32 trading days ago — a "golden cross", a bullish long-term signal | 32 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend) | 14.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 47, neither overbought (above 70) nor oversold (below 30) | 47.0 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($13.26 to $15.04) — its "stochastic" reading is 33 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 33.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 4 trading days ago (its momentum flipped negative) | 4 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $18.57 | $18.57 |
|---|---|---|
| From the 52-week high | it is 25.4% below its 52-week high (its highest price of the past year) | -25.4% |
| Above the 52-week low | it is 85.2% above its 52-week low (its lowest price of the past year) | +85.2% |
| Below the 52-week high | it is 25.4% below its highest point of the past year | 25.4% |
| Since a 20-day breakout | it made a new 20-day low about 15 trading days ago | 15 sessions |
| Since a 55-day breakout | it made a new 55-day high about 32 trading days ago | 32 sessions |
| All-time high | its highest closing price on record is $62.21 (set on 2024-03-08) | $62.21 |
| Given back of the 52-week move | over the past year its closes ranged ($7.79 to $18.11), and it has recovered a bit over half of its fall from last year’s high — 59% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $14.17 to $14.50. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. Worth noting that the whole move happened in 12 days, so it is a narrow thing to be measuring a retracement against. | 58.7% |
| From the all-time high | it is 77.7% below its all-time high | -77.7% |
| Nearest price level | it is trading 0.9% below a resistance level at $13.98 — a price it turned at three times since 2025-06-20, most recently on 2026-06-29. Since 2024-08-21 it has 8 such levels below the current price and 9 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.9% |
| All-time low | its lowest closing price on record is $5.42 (set on 2022-10-03) | $5.42 |
| Above the all-time low | it is 155.7% above its all-time low | +155.8% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 2% of the past ~6 months), which often precedes a bigger move | 2nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.8133 between its high and its low — about 5.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.8133 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $13.11 and $15.02 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $13.11 – $14.06 – $15.02 |
| Typical daily range (% of price) | its price moves about 5.9% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.9% |
| Stretch from the 200-day average | it is trading 3.0 daily ranges above its 200-day average price (21.7% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.0 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.10× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.6% since the prior reading | +0.6% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 4 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 4 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.7% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +0.7% |
|---|---|---|
| Open gap | it gapped 2.6% below the previous close 30 sessions ago and has not traded back through the level it left behind at 16.79 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -2.6% |
| Gap filled | a 2.7% gap up opened on 2026-08-19 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it took 1 session to close | 1 session ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 13.0 percentage points (the stock lost 10.7% while the market gained 2.3%) | -13.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 43.0 percentage points (the stock gained 46.1% while the market gained 3.1%) | +43.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 12.3 percentage points (the stock gained 23.3% while the market gained 11.1%) | +12.3% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 26.1 percentage points (the stock lost 5.7% while the market gained 20.5%) | -26.1% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 14.9% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 16% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $11.91 — a volume-weighted average of daily closes over 160 sessions, not a true tick-by-tick VWAP. | +16.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 2% below the average price paid since it last reported on 2026-08-10 (its 10-Q), so the typical buyer over that stretch is under water. That average is $14.14 — a volume-weighted average of daily closes over 10 sessions, not a true tick-by-tick VWAP. | -2.0% |
Price levels it has turned at before
BHVN last closed at $13.85 on 2026-08-21. Since 2024-08-21 it has turned at 8 prices below its last close and 9 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $13.98 | Resistance | 0.9% above the last close | turned there three times · 2025-06-20 to 2026-06-29 |
| $13.40 | Support | 3.2% below the last close | turned there twice · 2025-09-16 to 2025-09-25 |
| $13.06 | Support | 5.7% below the last close | turned there twice · 2025-07-16 to 2026-02-10 |
| $14.76 | Resistance | 6.6% above the last close | turned there twice · 2025-05-15 to 2025-10-14 |
| $12.81 | Support | 7.5% below the last close | turned there twice · 2025-07-29 to 2025-08-11 |
| $15.06 | Resistance | 8.8% above the last close | turned there twice · 2025-07-02 to 2026-08-13 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $15.79.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $9.87 and $12.13 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $15.79.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bearish (12/26/9) · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) · beating the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · bollinger bands
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.76 mean, 1=Strong Buy…5=Strong Sell) — 15 analysts
- Mean price target$23.07 range $10.00 – $50.00; median $20.00
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for BHVN
- Consensus EPS estimate-$0.6112 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant ongoing operating losses and a history of net losses with no guarantee of achieving or sustaining profitability.","Substantial reliance on the success of clinical-stage development programs which are subject to high failure rates.","Need for substantial additional capital to fund future operations and clinical trials."]
What changed in the latest 10-Q
AI-assisted comparison of BHVN's 10-Q filed 2026-05-04 against the prior one filed 2025-11-10.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-04) adds reference to 'Annual Report on Form 10-K for the year ended December 31, 2025' instead of 2024
- Newer filing adds 'obesity' as a separate therapeutic area in Overview section
- Newer filing describes strategic measures as 'portfolio and cost-optimization measures' versus 'strategic reprioritization'
- Newer filing removes 'mood disorders' from Kv7 ion channel modulation description
- Newer filing removes 'spinal muscular atrophy (SMA)' from myostatin-activin pathway description, keeping only 'neuromuscular and metabolic diseases, including obesity'
- Newer filing adds detailed MoDE and TRAP degrader section with specific clinical data on BHV-1300 and BHV-1400 programs
- Newer filing specifies BHV-1300 Phase 1 data: IgG reductions up to 87%, median maximum reductions of 83% within 18 days, 1000 mg weekly dose achieved up to 84% IgG reduction
- Newer filing reports BHV-1400 Phase 1 data showing deep, rapid lowering of Gd-IgA1 within hours with preservation of host immunoglobulins
- Newer filing states plans to initiate pivotal trials for BHV-1300 and BHV-1400 by mid-year 2026
- Removed:
- Older filing (2025-11-10) contains extensive Myostatin Platform and Taldefgrobep Alfa (BHV-2000) section with detailed Phase 3 trial results for SMA that is completely absent from newer filing
- Older filing contains detailed results from November 2024 Phase 3 SMA trial announcement showing non-statistical separation on primary outcome but clinical meaningfulness in subgroups, which is removed from newer filing
- Reworded:
- Reference changed from 'Exchange Act' alone to 'Section 21E of Exchange Act' in forward-looking statements disclaimer
- 'strategic reprioritization of our clinical development programs are now focused' changed to 'strategic portfolio and cost-optimization measures to prioritize'
- Therapeutic areas list order changed: older includes 'neuroscience' while newer separately lists 'obesity' as distinct area
- Notes:
- Newer filing is truncated and ends mid-sentence in BHV-1300 section, limiting complete comparison of Clinical-Stage Milestones content
- The removal of extensive SMA trial data and Myostatin Platform section may reflect either genuine portfolio changes or incomplete document transmission in newer filing
Risk Factors
- Added:
- Newer filing (2026-05-04) adds 'obesity' as a standalone therapeutic area in the business description, whereas older filing (2025-11-10) lists it only as part of the myostatin-activin pathway targeting agent description
- Removed:
- Older filing (2025-11-10) lists 'mood disorders' as an application for Kv7 ion channel modulation; newer filing (2026-05-04) removes this reference
- Older filing (2025-11-10) lists 'spinal muscular atrophy (SMA)' as an application for myostatin-activin pathway targeting agent; newer filing (2026-05-04) removes this specific reference
- Reworded:
- Nature of Business description reorganized: older filing (2025-11-10) includes 'mood disorders' and 'spinal muscular atrophy (SMA)' as specific indications; newer filing (2026-05-04) streamlines therapeutic areas to 'immunology, obesity, neuroscience, and oncology' without mood disorders or SMA explicitly mentioned
- Notes:
- Comparison limited to narrative sections provided; financial statements show different reporting periods (Q1 2026 vs. Q3 2025) and are not directly comparable
- Risk Factors section page numbers differ (41 vs. 54) but actual Risk Factors text was not provided in either filing excerpt, limiting assessment of that section
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
Most recent open-market transaction: 2025-03-04. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about BHVN's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Short interest (FINRA)
BHVN had 18,185,373 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
BHVN had 12.0% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.27 days to cover at the same settlement.
- Reported short interest (shares) 18,185,373
- Short interest (% of shares outstanding) 12.0%
- Prior settlement (shares) 19,345,532
- Reported change -6%
- Days to cover (reported) 9.27
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Amgen (AMGN)
- Biogen (BIIB)
- Eli Lilly (LLY)
- Regeneron Pharmaceuticals (REGN)
- Vertex Pharmaceuticals (VRTX)
- Roche (RHHBY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare BHVN vs…
BIOHAVEN LTD is found in…
Frequently asked questions
What does BIOHAVEN LTD (BHVN) do?
Biohaven is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics across immunology, obesity, neuroscience, and oncology. The company utilizes proprietary drug development platforms, including MoDE and TRAP technologies for extracellular protein degradation and Kv7 ion channel modulation.
What sector is BIOHAVEN LTD (BHVN) in?
BIOHAVEN LTD (BHVN) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NYSE.
Who are BIOHAVEN LTD's (BHVN) competitors?
Notable peers of BIOHAVEN LTD (BHVN) include Amgen, Biogen, Eli Lilly, Regeneron Pharmaceuticals and Vertex Pharmaceuticals. This peer set is informational only — not financial advice.
Is BIOHAVEN LTD (BHVN) overbought or oversold right now?
BIOHAVEN LTD (BHVN) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 47, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on BHVN come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.